Quinoline-based HIV integrase inhibitors

Current Pharmaceutical Design

Volumn 19, Issue 10, 2013, Pages 1835-1849

  Musiol, Robert ^a  

^a UNIVERSITY OF SILESIA   (Poland)

Author keywords

Diketoacids; HIV integrase inhibitors; Styrylquinoline

Indexed keywords

DOLUTEGRAVIR; ELVITEGRAVIR; GSK 364735; INTEGRASE INHIBITOR; L 870812; NALIDIXIC ACID; QUINOLINE DERIVATIVE; RALTEGRAVIR; UNCLASSIFIED DRUG; VIRUS DNA; ZIDOVUDINE;

DNA BINDING; DRUG DESIGN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO STUDY; LIPOPHILICITY; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; URINARY TRACT INFECTION;

HIV INTEGRASE; HIV INTEGRASE INHIBITORS; QUINOLONES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84876699717     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319100008     Document Type: Review

References (170)

1. Heeney JL, Dalgleish AG, Weiss RA. Origins of HIV and the evolution of resistance to AIDS. Science 2006; 313(5786): 462-6.
2. Weiss RA, Wrangham RW. From Pan to pandemic. Nature 1999; 397(6718): 385-6.
3. Keele BF, Van Heuverswyn F, Li Y, et al. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006; 313(5786): 523-6.
4. Curtin ME. Search for an AIDS virus: animal models. Microbiol Sci 1984; 1(2): 54.
5. Sarngadharan MG, DeVico AL, Bruch L, Schüpbach J, Gallo RC. HTLV-III: the etiologic agent of AIDS. Princess Takamatsu Symp 1984; 15: 301-8.
6. Furman PA, Barry DW. Spectrum of antiviral activity and mechanism of action of zidovudine. An overview. Am J Med 1988; 85(2A): 176-81.
7. Ramkumar K, Serrao E, Odde S, Neamati N. HIV-1 integrase inhibitors: 2007-2008 update. Med Res Rev 2010; 30(3): 890-954.
8. United Nation Program on HIV/AIDS [homepage on the internet] UNAIDS [cited 2012 march 15]; Available from: http: //www.unaids.org/en/
9. Barnard DL. Antiviral Research-15th International Conference. Mega-HAART and tenofovir. 17-21 March 2002, Prague, Czech Republic. IDrugs 2002; 5(5): 388-91.
10. Plipat N, Ruan PK, Fenton T, Yogev R. Rapid human immunodeficiency virus decay in highly active antiretroviral therapy (HAART)-experienced children after starting mega-HAART. J Virol 2004; 78(20): 11272-5.
11. May MT, Ingle SM. Life expectancy of HIV-positive adults: a review. Sex Health 2011; 8(4): 526-33.
12. Oster E. HIV and sexual behavior change: Why not Africa? J Health Econ 2012; 31(1): 35-49.
13. Delelis O, Carayon K, Saïb A, Deprez E, Mouscadet JF. Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology 2008; 5: 114.
14. Zervos P, Hassell T, Van Frank R, Lai MT. Characterization of an internally initiated integrase protein of HIV-1 produced in E. coli. Biochem Biophys Res Commun 1990; 170(3): 1061-6.
15. Rabson AB, Martin MA. Molecular organization of the AIDS retrovirus. Cell 1985; 40(3): 477-80.
16. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266(5193): 1981-6.
17. Maignan S, Guilloteau JP, Zhou-Liu Q, Clément-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol 1998; 282(2): 359-68.
18. Goldgur Y, Dyda F, Hickman AB, Jenkins TM, Craigie R, Davies DR. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium. Proc Natl Acad Sci USA 1998; 95(16): 9150-4.
19. Cai M, Zheng R, Caffrey M, Craigie R, Clore GM, Gronenborn AM. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat Struct Biol 1997; 4(7): 567-77.
20. Lodi PJ, Ernst JA, Kuszewski J, et al. Solution structure of the DNA binding domain of HIV-1 integrase. Biochemistry 1995; 34(31): 9826-33.
21. Wang JY, Ling H, Yang W, Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J 2001; 20(24): 7333-43.
22. Chen JC, Krucinski J, Miercke LJ, et al. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc Natl Acad Sci USA 2000; 97(15): 8233-8.
23. Hare S, Gupta SS, Valkov E, Engelman A, Cherepanov P. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010; 464(7286): 232-6.
24. Li X, Krishnan L, Cherepanov P, Engelman A. Structural biology of retroviral DNA integration. Virology 2011; 411(2): 194-205.
25. Hare S, Vos AM, Clayton RF, Thuring JW, Cummings MD, Cherepanov P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance. Proc Natl Acad Sci USA 2010; 107(46): 20057-62.
26. Maertens GN, Hare S, Cherepanov P. The mechanism of retroviral integration from X-ray structures of its key intermediates. Nature 2010; 468(7321): 326-9.
27. Cherepanov P. Integrase illuminated. EMBO Rep 2010; 11(5): 328.
28. Chow SA, Vincent KA, Ellison V, Brown PO. Reversal of integration and DNA splicing mediated by integrase of human immunodeficiency virus. Science 1992; 255(5045): 723-6.
29. Chow SA, Brown PO. Substrate features important for recognition and catalysis by human immunodeficiency virus type 1 integrase identified by using novel DNA substrates. J Virol 1994; 68(6): 3896-907.
30. Engelman A, Mizuuchi K, Craigie R. HIV-1 DNA integration: mechanism of viral DNA cleavage and DNA strand transfer. Cell 1991; 67(6): 1211-21.
31. Skinner LM, Sudol M, Harper AL, Katzman M. Nucleophile selection for the endonuclease activities of human, ovine, and avian retroviral integrases. J Biol Chem 2001; 276(1): 114-24.
32. Guiot E, Carayon K, Delelis O, et al. Relationship between the oligomeric status of HIV-1 integrase on DNA and enzymatic activity. J Biol Chem 2006; 281(32): 22707-19.
33. Faure A, Calmels C, Desjobert C, et al. HIV-1 integrase crosslinked oligomers are active in vitro. Nucleic Acids Res 2005; 33(3): 977-86.
34. Lee SP, Xiao J, Knutson JR, Lewis MS, Han MK. Zn2+ promotes the self-association of human immunodeficiency virus type-1 integrase in vitro. Biochemistry 1997; 36(1): 173-80.
35. Zheng R, Jenkins TM, Craigie R. Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci USA 1996; 93(24): 13659-64.
36. Priel E, Showalter SD, Blair DG. Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor. AIDS Res Hum Retroviruses 1991; 7(1): 65-72.
37. Carteau S, Mouscadet JF, Goulaouic H, Subra F, Auclair C. Effect of topoisomerase inhibitors on the in vitro HIV DNA integration reaction. Biochem Biophys Res Commun 1993; 192(3): 1409-14.
38. LaFemina RL, Graham PL, LeGrow K, et al. Inhibition of human immunodeficiency virus integrase by bis-catechols. Antimicrobial Agents Chemother 1995; 39(2): 320-4.
39. Fesen MR, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, Kohn KW. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994; 48(3): 595-608.
40. Fesen MR, Kohn KW, Leteurtre F, Pommier Y. Inhibitors of human immunodeficiency virus integrase. Proc Natl Acad Sci USA 1993; 90(6): 2399-403.
41. Puras Lutzke R, Eppens N, Weber P, Houghten R, Plasterk RH. Identification of a hexapeptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial chemical library. Proc Natl Acad Sci USA 1995; 92(25): 11456-60.
42. Zhao L, O'reily MK, Shultz MD, Chmielewski J. Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. Bioorg Med Chem Lett 2003; 13(6): 1175-7.
43. Oz Gleenberg I, Avidan O, Goldgur Y, Herschorn A, Hizi A. Peptides derived from the reverse transcriptase of human immunodeficiency virus type 1as novel inhibitors of the viral integrase. J Biol Chem 2005; 280(23): 21987-96
44. Li HY, Zawahir Z, Song LD, Long YQ, Neamati N. Sequencebased design and discovery of peptide inhibitors of HIV 1 integrase: insight into the binding mode of the enzyme. J Med Chem 2006; 49(15): 4477-86.
45. Hayouka Z, Levin A, Maes M, et al. Mechanism of action of the HIV-1 integrase inhibitory peptide LEDGF 361-370. Biochem Biophys Res Commun2010; 394(2): 260-5.
46. Hayouka Z, Rosenbluh J, Levin A, Maes M, Loyter A, Friedler A. Peptides derived from HIV-1 Rev inhibit HIV-1 integrase in a shiftide mechanism. Biopolymers 2008; 90(4): 481-7.
47. Hayouka Z, Hurevich M, Levin A, et al. Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein. Bioorg Med Chem 2010; 18(23): 8388-95.
48. Carteau S, Mouscadet JF, Goulaouic H, Subra F, Auclair C. Inhibitory effect of the polyanionic drug suramin on the in vitro HIV DNA integration reaction. Arch Biochem Biophys 1993; 305(2): 606-10.
49. Cushman M, Sherman P. Inhibition of HIV-1 integration protein by aurintricarboxylic acid monomers, monomer analogs, and polymer fractions. Biochemic Biophys Res Commun 1992; 185(1): 85-90.
50. Lipford JR, Worland ST, Farnet CM. Nucleotide binding by the HIV-1 integrase protein in vitro. J Acquir Immune Defic Syndr 1994; 7(12): 1215-23.
51. Mazumder A, Cooney D, Agbaria R, Gupta M, Pommier Y. Inhibition of human immunodeficiency virus type 1 integrase by 3'-azido-3'-deoxythymidylate. Proc Natl Acad Sci USA 1994; 91(13): 5771-5.
52. Drake RR, Neamati N, Hong H, et al. Identification of a nucleotide binding site in HIV-1 integrase. Proc Natl Acad Sci USA 1998; 95(8): 4170-5.
53. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of Strand Transfer That Prevent Integration and Inhibit HIV-1 Replication in Cells. Science 2000; 287(5453): 646-50.
54. Espeseth AS, Felock P, Wolfe A, et al. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase. Proc Natl Acad Sci USA 2000; 97(21): 11244-9.
55. Serrao E, Odde S, Ramkumar K, Neamati N. Raltegravir, elvitegravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors. Retrovirology 2009; 6: 25.
56. Tan J J, Cong XJ, Hu LM, Wang CX, Jia L, Liang XJ. Therapeutic strategies underpinning the development of novel techniques for the treatment of HIV infection. Drug Discov Today 2010; 15(5-6): 186-97.
57. Powderly WG. Integrase inhibitors in the treatment of HIV-1 infection. J Antimicrobial Chemother 2010; 65(12): 2485-8.
58. Luo ZG, Tan JJ, Zeng Y, Wang CX, Hu LM. Development of integrase inhibitors of quinolone acid derivatives for treatment of AIDS: an overview. Mini Rev Med Chem 2010; 10(11): 1046-57.
59. Dayam R, Gundla R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: 2005-2006 update. Med Res Rev 2008; 28(1): 118-54.
60. Dayam R, Al-Mawsawi LQ, Neamati N. HIV-1 integrase inhibitors: an emerging clinical reality. Drugs R D 2007; 8(3): 155-68.
61. Andonie R, Fabry-Asztalos L, Abdul-Wahid CB, Abdul-Wahid S, Barker GI, Magill LC. Fuzzy ARTMAP prediction of biological activities for potential HIV-1 protease inhibitors using a small molecular data set. IEEE/ACM Trans Comput Biol Bioinform 2011; 8(1): 80-93.
62. Goodarzi M, Freitas MP. MIA-QSAR coupled to principal component analysis-adaptive neuro-fuzzy inference systems (PCAANFIS) for the modeling of the anti-HIV reverse transcriptase activities of TIBO derivatives. Eur J Med Chem 2010; 45(4): 1352-8.
63. Johnson MA, Maggiora GM, Eds. Concepts and applications of molecular similarity. New York: John Wiley & Sons 1990.
64. Evans BE, Rittle KE, Bock MG, et al. Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists. J Med Chem 1988; 31(12): 2235-46.
65. Patchett AA, Nargund RP. Privileged structures-An update. In: Annual Reports in Medicinal Chemistry, Vol 35. Elsevier Inc.; 2000. p. 289-98.
66. DeSimone RW, Currie KS, Mitchell SA, Darrow JW, Pippin D a. Privileged structures: applications in drug discovery. Comb Chem High Throughput Screen 2004; 7(5): 473-94.
67. Bondensgaard K, Ankersen M, Thøgersen H, Hansen BS, Wulff BS, Bywater RP. Recognition of privileged structures by G-protein coupled receptors. J Med Chem 2004; 47(4): 888-99.
68. Duarte CD, Barreiro EJ, Fraga CAM. Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem 2007; 7(11): 1108-19.
69. Horton DA, Bourne GT, Smythe ML. The combinatorial synthesis of bicyclic privileged structures or privileged substructures. Chem Rev 2003; 103(3): 893-930.
70. Costantino L, Barlocco D. Privileged structures as leads in medicinal chemistry. Curr Med Chem 2006; 13(1): 65-85.
71. Che Y, Marshall GR. Privileged scaffolds targeting reverse-turn and helix recognition. Expert Opin Ther Targets 2008; 12(1): 101-14.
72. Austin JF, MacMillan DWC. Enantioselective organocatalytic indole alkylations. Design of a new and highly effective chiral amine for iminium catalysis. J Am Chem Soc 2002; 124(7): 1172-3.
73. Hajduk PJ, Bures M, Praestgaard J, Fesik SW. Privileged molecules for protein binding identified from NMR-based screening. J Med Chem2000; 43(18): 3443-7.
74. Barakat KJ, Cheng K, Chan WW, et al. Synthesis and biological activities of phenyl piperazine-based peptidomimetic growth hormone secretagogues. Bioorg Med Chem Lett 1998; 8(11): 1431-6.
75. Jacobson KA, Kim Y ong-C, King BF. In search of selective P2 receptor ligands: interaction of dihydropyridine derivatives at recombinant rat P2X(2) receptors. J Auton Nerv Syst 2000; 81(1-3): 152-7.
76. Nicolaou KC, Pfefferkorn JA, Roecker AJ, Cao GQ, Barluenga S, Mitchell HJ. Natural Product-like Combinatorial Libraries Based on Privileged Structures. 1. General Principles and Solid-Phase Synthesis of Benzopyrans. J Am Chem Soc 2000; 122(41): 9939-53.
77. Nicolaou KC, Roecker AJ, Barluenga S, Pfefferkorn JA, Cao GQ. Discovery of novel antibacterial agents active against methicillinresistant Staphylococcus aureus from combinatorial benzopyran libraries. Chembiochem 2001; 2(6): 460-5.
78. Liu Z, Chen X, Yu L, Zhen X, Zhang A. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg Med Chem 2008; 16(14): 6675-81.
79. Welsch ME, Snyder S, Stockwell BR. Privileged scaffolds for library design and drug discovery. Current Opin Chem Biol 2010; 14(3): 1-15.
80. Willoughby C a, Hutchins SM, Rosauer KG, et al. Combinatorial synthesis of 3-(amidoalkyl) and 3-(aminoalkyl)-2-arylindole derivatives: discovery of potent ligands for a variety of G-protein coupled receptors. Bioorg Med Chem Lett 2002; 12(1): 93-6.
81. Chang YT, Gray NS, Rosania GR, et al. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. Chem Biol 1999; 6(6): 361-75.
82. Lee J-Y, Kim Y-C. Combinatorial library synthesis and biological evaluation of pyrazolo[4,3-e][1,4]diazepine as a potential privileged structure. Chem Med Chem 2009; 4(5): 733-7.
83. Bunin BA, Plunkett MJ, Ellman JA. The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library. Proc Natl Acad Sci USA 1994; 91(11): 4708-12.
84. Schnur DM, Hermsmeier MA, Tebben AJ. Are target-familyprivileged substructures truly privileged? J Med Chem 2006; 49(6): 2000-9.
85. Polanski J, Kurczyk A, Bak A, Musiol R. Privileged structures-dream or reality: preferential organization of azanaphthalene scaffold. Curr Med Chem 2012; 19(13): 1921-45.
86. Bemis GW, Murcko MA. The properties of known drugs. 1. Molecular frameworks. J Med Chem 1996; 39(15): 2887-93.
87. Klopman G. Artificial intelligence approach to structure-activity studies. Computer automated structure evaluation of biological activity of organic molecules. J Am Chem Soc 1984; 106(24): 7315-21.
88. Lewell XQ, Judd DB, Watson SP, Hann MM. RECAP--retrosynthetic combinatorial analysis procedure: a powerful new technique for identifying privileged molecular fragments with useful applications in combinatorial chemistry. J Chem Inf Comput Sci 1998; 38(3): 511-22.
89. Bongarzone S, Bolognesi ML. The concept of privileged structures in rational drug design: focus on acridine and quinoline scaffolds in neurodegenerative and protozoan diseases. Expert Opin Drug Discov 2011; 6(3): 251-68.
90. Petersen U. Quinolone Antibiotics: The Development of Moxifloxacin. In: Fischer J, Ganellin CR, Eds. Analogue-based Drug Discovery. Weinheim: Wiley-VCH Verlag 2006; pp. 315-70.
91. Grundon MF. Quinoline, quinazoline, and acridone alkaloids. Nat Prod Rep 1988; 5(3): 293-307.
92. Grundon MF. Quinoline, quinazoline, and acridone alkaloids. Nat Prod Rep 1990; 7(2): 131.
93. Michael JP. Quinoline, quinazoline and acridone alkaloids. Nat Prod Rep 2008; 25(1): 166-87.
94. Musiol R, Magdziarz T, Kurczyk A. Quinoline scaffold as a privileged substructure in antimicrobial drugs. In: Mendez-Vilas A, Ed. Science against microbial pathogens: communicating current research and technological advances. Badajoz, Spain: Formatex 2011; pp. 72-83.
95. Musiol R, Serda M, Hensel-Bielowka S, Polanski J. Quinolinebased antifungals. Curr Med Chem 2010; 17(18): 1960-73.
96. Rhodes DI, Peat TS, Vandegraaff N, et al. Structural basis for a new mechanism of inhibition of HIV-1 integrase identified by fragment screening and structure-based design. Antivir Chem Chemother 2011; 21(4): 155-68.
97. Al-Mawsawi LQ, Neamati N. Allosteric inhibitor development targeting HIV-1 integrase. ChemMedChem 2011; 6(2): 228-41.
98. Kessl JJ, Eidahl JO, Shkriabai N, et al. An allosteric mechanism for inhibiting HIV-1 integrase with a small molecule. Mol Pharmacol 2009; 76(4): 824-32.
99. Grobler JA, Stillmock K, Hu B, et al. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proc Natl Acad Sci USA 2002; 99(10): 6661-6.
100. Bacchi A, Carcelli M, Compari C, et al. HIV-1 IN strand transfer chelating inhibitors: a focus on metal binding. Mol Pharm 2011; 8(2): 507-19.
101. Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. J Med Chem 2011; 54(24): 8407-20.
102. Ma XH, Zhang XY, Tan JJ, Chen WZ, Wang CX. Exploring binding mode for styrylquinoline HIV-1 integrase inhibitors using comparative molecular field analysis and docking studies. Acta Pharmacol Sin 2004; 25(7): 950-8.
103. Maurin C, Bailly F, Buisine E, et al. Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site. J Med Chem 2004; 47(22): 5583-6.
104. Mouscadet J-F, Tchertanov L. Raltegravir: molecular basis of its mechanism of action. Eur J Med Res 2009; 14 Suppl 3: 5-16.
105. Pandey KK, Grandgenett DP. HIV-1 Integrase Strand Transfer Inhibitors: Novel Insights into their Mechanism of Action. Retrovirology 2008; 2: 11-6.
106. Bera S, Pandey KK, Vora AC, Grandgenett DP. HIV-1 integrase strand transfer inhibitors stabilize an integrase-single blunt-ended DNA complex. J Mol Biol 2011; 410(5): 831-46.
107. Karpićska G, Mazurek AP, Dobrowolski JC. On tautomerism and substituent effect in 8-hydroxyquinoline-derived medicine molecules. Theochem 2010; 961(1-3): 101-6.
108. Bodor N, Dewar MJS, Harget AJ. Ground states of conjugated molecules. XIX. Tautomerism of heteroaromatic hydroxy and amino derivatives and nucleotide bases. J Am Chem Soc 1970; 92(10): 2929-36.
109. Tokay N. Quantum chemical studies on tautomerism of 2-, 3-or 4-hydroxyquinoline derivatives along with their thio and azo analogs. Theochem 2002; 594(3): 185-97.
110. Ouali M, Laboulais C, Leh H, et al. Tautomers of styrylquinoline derivatives containing a methoxy substituent: Computation of their population in aqueous solution and their interaction with RSV integrase catalytic core. Acta Biochim Pol 2000; 47(1): 11-22.
111. Gudat D, Nycz JE, Polanski J. A solid state and solution NMR study of the tautomerism in hydroxyquinoline carboxylic acids. Magn Reson Chem 2008; 46 Suppl 1: S115-9.
112. Paretzki A, Das HS, Weisser F, et al. Invariant oxidation state of copper but not of ruthenium in complexes with noninnocent N-(2-Methyl-5,8-dioxo-5,8-dihydroquinolin-7-yl)acetamide: A combined structural, electrochemical and spectroelectrochemical investigation. Eur J Inorg Chem 2011; 2011(15): 2413-21.
113. Nycz JE, Malecki G, Ponikiewski L, Leboschka M, Nowak M, Kusz J. Synthesis, spectroscopy and computational studies of some novel phosphorylated derivatives of quinoline-5,8-diones. J Mol Struct 2011; 986(1-3): 39-48.
114. Ponikiewski L, Nycz JE. 3-[(E)-2-(5,7-Dichloro-8-hydroxyquinolin-2-yl)vin-yl]-4-hydroxy-phenyl acetate. Acta Crystallogr Sect E 2009; 65(Pt3): 515.
115. Majerz-Maniecka K, Musiol R, Nitek W, et al. Intermolecular interactions in the crystal structures of potential HIV-1 integrase inhibitors. Bioorg Med Chem Lett 2006; 16(4): 1005-9.
116. Kim TG, Kim Y, Jang DJ. Catalytic Roles of Water Protropic Species in the Tautomerization of Excited 6-Hydroxyquinoline: Migration of Hydrated Proton Clusters. J Phys Chem A 2001; 105(17): 4328-32.
117. Kohtani S, Tagami A, Nakagaki R. Excited-state proton transfer of 7-hydroxyquinoline in a non-polar medium: mechanism of triple proton transfer in the hydrogen-bonded system. Chem Phys Lett 2000; 316(1-2): 88-93.
118. Al-Lawatia N, Husband J, Steinbrecher T, Abou-Zied OK. Tautomerism in 7-hydroxyquinoline: a combined experimental and theoretical study in water. J Phys Chem A 2011; 115(17): 4195-201.
119. Chou PT, Wei CY, Chris Wang CR, Hung FT, Chang CP. Proton-Transfer Tautomerism of 7-Hydroxyquinolines Mediated by Hydrogen-Bonded Complexes. J Phys Chem A 1999; 103(13): 1939-49.
120. Filip EM, Humelnicu IV, Ghirvu CI. Some Aspects of 8-hydroxyquinoline in Solvents. Acta Chem 2009; 17: 85-96.
121. Zouhiri F, Desmaële D, D'Angelo J, et al. HIV-1 replication inhibitors of the styrylquinoline class: incorporation of a masked diketo acid pharmacophore. Tetrahedron Lett 2001; 42(46): 8189-92.
122. Zheng C, Niu L, Ping L, Zhong D. Design and Synthesis of 2-Styrylquinoline-7-sulfonamide Derivatives as Potential HIV Integrase Inhibitors. Chin J Org Chem 2009; 29: 1105-14.(Chinese)
123. Jiao ZG, He HQ, Zeng CC, Tan JJ, Hu LM, Wang CX. Design, synthesis and anti-HIV integrase evaluation of N-(5-chloro-8-hydroxy-2-styrylquinolin-7-yl)benzenesulfonamide derivatives. Molecules 2010; 15(3): 1903-17.
124. Zouhiri F, Danet M, Bénard C, et al. HIV-1 replication inhibitors of the styrylquinoline class: introduction of an additional carboxyl group at the C-5 position of the quinoline. Tetrahedron Lett 2005; 46(13): 2201-5.
125. Normand-Bayle M, Bénard C, Zouhiri F, et al. New HIV-1 replication inhibitors of the styryquinoline class bearing aroyl/acyl groups at the C-7 position: synthesis and biological activity. Bioorg Med Chem Lett 2005; 15(18): 4019-22.
126. Bénard C, Zouhiri F, Normand-Bayle M, et al. Linker-modified quinoline derivatives targeting HIV-1 integrase: synthesis and biological activity. Bioorg Med Chem Lett 2004; 14(10): 2473-6.
127. Hazuda DJ, Anthony NJ, Gomez RP, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA 2004; 101(31): 11233-8.
128. Jin H, Cai RZ, Schacherer L, et al. Design, synthesis, and SAR studies of novel and highly active tri-cyclic HIV integrase inhibitors. Bioorg Med Chem Lett 2006; 16(15): 3989-92.
129. Jin H, Metobo S, Jabri S, et al. Tricyclic HIV integrase inhibitors V. SAR studies on the benzyl moiety. Bioorg Med Chem Lett 2009; 19(8): 2263-5.
130. Metobo SE, Jin H, Tsiang M, Kim CU. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring. Bioorg Med Chem Lett 2006; 16(15): 3985-8.
131. Jin H, Wright M, Pastor R, et al. Tricyclic HIV integrase inhibitors: potent and orally bioavailable C5-aza analogs. Bioorg Med Chem Lett 2008; 18(4): 1388-91.
132. Jones GS, Yu F, Zeynalzadegan A, et al. Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase. Antimicrobial Agents Chemother 2009; 53(3): 1194-203.
133. Metobo S, Mish M, Jin H, et al. Tricyclic HIV integrase inhibitors: VI. SAR studies of "benzyl flipped" C3-substituted pyrroloquinolines. Bioorg Med Chem Lett 2009; 19(4): 1187-90.
134. Polanski J, Niedbala H, Musiol R, et al. Fragment Based Approach for the Investigation of HIV-1 Integrase Inhibition. Lett Drug Des Discov 2007; 4(2): 99-105.
135. Polanski J, Niedbala H, Musiol R, et al. 5-Hydroxy-6-Quinaldic Acid as a Novel Molecular Scaffold for HIV-1 Integrase Inhibitors. Lett Drug Des Discov 2006; 3(3): 175-8.
136. Mouscadet J-F, Desmaële D. Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors. Molecules 2010; 15: 3048-78.
137. Zouhiri F, Mouscadet JF, Mekouar K, et al. Structure-activity relationships and binding mode of styrylquinolines as potent inhibitors of HIV-1 integrase and replication of HIV-1 in cell culture. J Med Chem 2000; 43(8): 1533-40.
138. Courcot B, Firley D, Fraisse B, et al. Crystal and electronic structures of magnesium(II), copper(II), and mixed magnesium(II)-copper(II) complexes of the quinoline half of styrylquinoline-type HIV-1 integrase inhibitors. J Phys Chem B 2007; 111(21): 6042-50.
139. Niedbala H, Polanski J, Gieleciak R, et al. Comparative molecular surface analysis (CoMSA) for virtual combinatorial library screening of styrylquinoline HIV-1 blocking agents. Comb Chem High Throughput Screen 2006; 9(10): 753-70.
140. Mekouar K, Mouscadet JF, Desmaële D, et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem 1998; 41(15): 2846-57.
141. Yoo H, Lee JY, Park JH, Chung BY, Lee YS. Synthesis of styrylbenzofuran derivatives as styrylquinoline analogues for HIV-1 integrase inhibitor. Farmaco 2003; 58(12): 1243-50.
142. Lee JY, Park JH, Lee SJ, Park H, Lee YS. Styrylquinazoline derivatives as HIV-1 integrase inhibitors. Arch Pharm 2002; 335(6): 277-82.
143. Polanski J, Niedbala H, Musiol R, et al. Analogues of styrylquinoline and styrylquinazoline HIV-1 integrase inhibitors: design and synthetic problems. Acta Pol Pharm Drug Res 2004; 61: 3-4.
144. Polanski J, Zouhiri F, Jeanson L, et al. Use of the Kohonen neural network for rapid screening of ex vivo anti-HIV activity of styrylquinolines. J Med Chem 2002; 45(21): 4647-54.
145. Majerz-Maniecka K, Musiol R, Skórska-Stania A, et al. X-ray and molecular modelling in fragment-based design of three small quinoline scaffolds for HIV integrase inhibitors. Bioorg Med Chem 2011; 19(5): 1606-12.
146. Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother 2003; 51 Suppl 1: 1-11.
147. Baba M, Pauwels R, Balzarini J, Schols D, De Clercq E. Coumermycin A1 is a potent inhibitor of human immunodeficiency virus (HIV) replication in vitro. Int J Exp Clin Chemother 1989; 2: 15-20.
148. Tachedjian G, Tyssen D, Locarnini S, Gust I, Birch C. Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: inhibition by coumermycin A1. Antivir Chem Chemother 1009; 1(2): 131-8.
149. Hagihara M, Kashiwase H, Katsube T, et al. Synthesis and anti-HIV activity of arylpiperazinyl fluoroquinolones: a new class of anti-HIV agents. Bioorg Med Chem Lett 1999; 9(21): 3063-8.
150. Tabarrini O, Massari S, Daelemans D, et al. Structure-activity relationship study on anti-HIV 6-desfluoroquinolones. J Med Chem 2008; 51(17): 5454-8.
151. Massari S, Daelemans D, Manfroni G, et al. Studies on anti-HIV quinolones: new insights on the C-6 position. Bioorg Med Chem 2009; 17(2): 667-74.
152. Lampiris HW. Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor. Expert Rev Anti Infect Ther 2012; 10(1): 13-20.
153. Sato M, Kawakami H, Motomura T, et al. Quinolone carboxylic acids as a novel monoketo acid class of human immunodeficiency virus type 1 integrase inhibitors. J Med Chem 2009; 52(15): 4869-82.
154. Maurin C, Bailly F, Buisine E, et al. Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site. J Med Chem 2004; 47(22): 5583-6.
155. Di Santo R, Costi R, Roux A, et al. Novel bifunctional quinolonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, biological activities, and mechanism of action. J Med Chem 2006; 49(6): 1939-45.
156. Johnson AA, Marchand C, Patil SS, et al. Probing HIV-1 integrase inhibitor binding sites with position-specific integrase-DNA crosslinking assays. Mol Pharmacol 2007; 71(3): 893-901.
157. Podtelezhnikov AA, Gao K, Bushman FD, McCammon JA. Modeling HIV-1 integrase complexes based on their hydrodynamic properties. Biopolymers 2003; 68: 110-20.
158. Di Santo R, Costi R, Roux A, et al. Novel quinolinonyl diketo acid derivatives as HIV-1 integrase inhibitors: design, synthesis, and biological activities. J Med Chem 2008; 51(15): 4744-50.
159. Vandurm P, Guiguen A, Cauvin C, et al. Synthesis, biological evaluation and molecular modeling studies of quinolonyl diketo acid derivatives: new structural insight into the HIV-1 integrase inhibition. Eur J Med Chem 2011; 46(5): 1749-56.
160. Vandurm P, Cauvin C, Guiguen A, et al. Structural and theoretical studies of [6-bromo-1-(4-fluorophenylmethyl)-4(1H)-quinolinon-3-yl)]-4-hydroxy-2-oxo-3-butenoïc acid as HIV-1 integrase inhibitor. Bioorg Med Chem Lett 2009; 19(16): 4806-9.
161. Wang Z, Vince R. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase. Bioorg Med Chem Lett 2008; 18(4): 1293-6.
162. Wang Z, Tang J, Salomon CE, Dreis CD, Vince R. Pharmacophore and structure-activity relationships of integrase inhibition within a dual inhibitor scaffold of HIV reverse transcriptase and integrase. Bioorg Med Chem 2010; 18(12): 4202-11.
163. Sechi M, Rizzi G, Bacchi A, et al. Design and synthesis of novel dihydroquinoline-3-carboxylic acids as HIV-1 integrase inhibitors. Bioorg Med Chem 2009; 17(7): 2925-35.
164. Dayam R, Sanchez T, Neamati N. Diketo acid pharmacophore. 2. Discovery of structurally diverse inhibitors of HIV-1 integrase. J Med Chem 2005; 48(1): 8009-15.
165. Dayam R, Sanchez T, Clement O, Shoemaker R, Sei S, Neamati N. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J Med Chem 2005; 48(1): 111-20.
166. Dayam R, Al-Mawsawi LQ, Zawahir Z, Witvrouw M, Debyser Z, Neamati N. Quinolone 3-carboxylic acid pharmacophore: design of second generation HIV-1 integrase inhibitors. J Med Chem 2008; 51(5): 1136-44.
167. Bacchi A, Biemmi M, Carcelli M, et al. From ligand to complexes. Part 2. Remarks on human immunodeficiency virus type 1 integrase inhibition by beta-diketo acid metal complexes. J Med Chem 2008; 51(22): 7253-64.
168. Pasquini S, Mugnaini C, Tintori C, et al. Investigations on the 4-quinolone-3-carboxylic acid motif. 1. Synthesis and structureactivity relationship of a class of human immunodeficiency virus type 1 integrase inhibitors. J Med Chem 2008; 51(16): 5125-9.
169. Zeng J, Lu X, Zeng C, Hu L, Zhong R. Design, Synthesis and Anti-HIV Integrase Evaluation of 1,2,3-Triazol-4-yl-substituted 1,4-Dihydro-4-oxo-1,5-napthyridine-3-carboxylic Acids. Chin J Chem 2009; 27(5): 953-62.
170. He QQ, Gu SX, Liu J, et al. Structural modifications of quinolone-3-carboxylic acids with anti-HIV activity. Bioorg Med Chem 2011; 19(16): 5039-45.